Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma - LARVOL DELTA

Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3-11 Years With Chronic Hepatitis C: A Real-World, Prospective, Multicenter Study in Japan. (PubMed, Hepatol Res) - "In real-world clinical practice, G/P treatment demonstrated high efficacy and good tolerability in children aged 3-11 years with chronic HCV."

Clinical • Journal • Real-world evidence • Hepatitis C • Infectious Disease • Inflammation • Pediatrics • LGALS3BP

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1/2 trial • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Prevalence, clinical correlations and outcomes of Cryoglobulinemic Vasculitis: a retrospective monocentric study (2013–2023) (EULAR 2025) - "Since the introduction of pan-genotypic regimens for the treatment of HCV in 2017 (e.g., Sofosbuvir/Velpatasvir and Glecaprevir/Pibrentasvir), the mean incidence of CV decreased from 8.4 cases (±1.7) during the period 2013–2017 to 3 cases (±1.6) during the period 2018–2023 ( p-value 0.001 )...Two-thirds of patients with CryoVas related to ADs received Rituximab (RTX), while Belimumab (BEL) was used exclusively in CryoVas related to ADs and essential CryoVas (10% and 8%, respectively)... CryoVas remains a significant clinical condition, with its etiology progressively evolving in recent years. Treatment approaches varied by etiology, with RTX serving as a cornerstone for CryoVas associated with ADs, while BEL demonstrated potential in select cases. Despite advancements in treatment and high rate of complete clinical response, relapse rates remain high, particularly in autoimmune-related CryoVas."

Retrospective data • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Rheumatology • Sjogren's Syndrome • Vasculitis

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus (PRNewswire) - "AbbVie...announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate....The label expansion was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVYRET eight-week treatment in adults with acute HCV infection."

FDA approval • Hepatitis C • Infectious Disease

The experience and outcomes of our centre’s first year accepting Hepatitis C positive deceased donor kidneys for transplantation (UKKW 2025) - "She then underwent a 16-week course of Epclusa to ensure a sustained virological response at 12 weeks following completion of treatment (SV12), and has successfully achieved SV12 clearance...She completed a 16-week course of Maviret with sustained virological response and no second course of treatment required...Of those that have gone ahead, 2 of 5 patients have developed active viraemia and both of these have been successfully treated. We are encouraged by this small number of results and will continue with this programme in the hopes that more of our patients will consent to HCV-positive donor kidneys in future, with ongoing good outcomes."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Unexpected Findings of Liver Cirrhosis in Bariatric Surgery Patients: A Retrospective Analysis of Three Clinical Cases (ECO 2025) - "After antiviral therapy (Glecaprevir/Pibrentasvir 12 weeks in standard doses), no viral load was detected... Undiagnosed liver cirrhosis can present unexpected challenges in bariatric surgery. Preoperative assessment should incorporate advanced diagnostic modalities, such as liver fibrosis calculators and elastography/MRI, especially in high-risk patients. Despite intraoperative findings, LSG proved to be a safe and effective procedure for weight loss and metabolic improvement in patients with compensated cirrhosis."

Bariatric surgery • Retrospective data • Surgery • Cardiovascular • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Obesity • Portal Hypertension • Thrombocytopenia • Type 2 Diabetes Mellitus

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION WITH GLECAPREVIR/PIBRENTASVIR IN PEDIATRIC AGE - THE REALITY OF A LEVEL III HOSPITAL (ESPGHAN 2025) - "At 12 weeks, SVR was confirmed in 8/8 patients. Conclusions Direct-acting antivirals provide an opportunity to treat HCV at earlier ages with shorter regimens, achieving high cure rates and no side effects."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Oncology • Pediatrics • Solid Tumor

GLECAPREVIR-PIBRENTASVIR IMPLEMENTATION FOR CHILDREN AGED 3-12 YEARS WITH CHRONIC HEPATITIS C: MULTICENTER REAL-WORLD DATA. (ESPGHAN 2025) - "Conclusions Our real-world data support clinical trials, showing GLE/PIB to be effective and well-tolerated for children aged 3-12 with chronic HCV. Early treatment may help prevent liver damage and lower transmission rates."

Clinical • Real-world • Real-world evidence • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics

COMPARATIVE STUDY DEMONSTRATING THE SUPERIORITY OF DIRECT-ACTING ANTIVIRALS OVER INTERFERON PLUS RIBAVIRIN IN ALBANIAN CHILDREN WITH CHRONIC HEPATITIS C (ESPGHAN 2025) - "The second group, comprising children aged 4 to 22*years (10 boys and 2 girls), [table 2] was treated with DAAs: half received HARVONI (Ledipasvir/Sofosbuvir) for 12 weeks, and the other half received MAVYRET (Glecaprevir/Pibrentasvir) for 8 weeks. They resulted in fewer side effects and shorter treatment duration. These findings highlight the superiority of DAAs and support the WHO recommendations for treating adults, adolescents, and children as young as 3 years old."

Clinical • Head-to-Head • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pain • Pediatrics

TEMPORAL TRENDS IN HCV SCREENING, FOLLOW-UP TESTING, AND TREATMENT IN PREGNANT PEOPLE AND INFANTS IN AN ACADEMIC COUNTY HOSPITAL SETTING (DDW 2025) - "Of the 13 (25.5%) with HCV-related consults, none received antiviral therapy during pregnancy; 1 (7.7%) received postpartum antiviral therapy (with glecaprevir/pibrentasvir), and 12 (92.3%) were lost to follow-up... HCV screening in pregnancy has improved to 79.4% over the past 10 years, although remained lower than universal recommendations. While HCV viremia was < 1%, with no perinatal transmission, infant screening rates were low at 26%. This data supports the increased need for linkage of care for HCV infected birthing parents and infants, to enhance access to HCV screening and eradication."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Inflammation

RISK OF HEPATOCELLULAR CARCINOMA AFTER RECEIVING DIRECT ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS: MULTICENTRIC RETROSPECTIVE STUDY (DDW 2025) - "Subgroup analyses were performed for specific DAAAs combinations (Epclusa, Harvoni, Mavyret, Vosevi, and Zepatier). The findings highlight the importance of early DAAAs treatment in reducing the long-term complications of HCV. Further prospective studies with longer follow-up durations are warranted to confirm these associations."

Retrospective data • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study (EASL 2025) - "Most of the patients had been pre-treated with VEL/SOF (55%, 17/31), 13% (4/31) each had received G/P (glecaprevir/pibrentasvir) or GZR/EBR(grazoprevir/elbasvir)±SOF and 10% (3/31) each had been pretreated with LDV(ledipasvir)/SOF or DCV(daclatasvir)/SOF. The combination of G/P+SOF represents an effective third-line treatment option for difficult-to-treat patients, including those with cirrhosis, HCC, or HCV GT3 infection. These findings highlight the importance of tailored salvage therapy to achieve optimal outcomes in this challenging population."

Clinical • Real-world • Real-world evidence • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety. (PubMed, J Clin Med) - " This single-center study supports the safety of kidney transplantation from HCV-positive donors. Preemptive Glecaprevir/Pibrentasvir therapy effectively prevents HCV transmission, offering a viable option to expand the donor pool."

Journal • Retrospective data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Transplantation

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder (clinicaltrials.gov) - P2/3 | N=92 | Recruiting | Sponsor: White River Junction Veterans Affairs Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s) (EASL 2025) - No abstract available

Clinical • Hepatitis C • Infectious Disease

Therapy of HCV infections among patients of ukrainian origin during the influx of war refugees to Poland (EASL 2025) - "Patients regardless of nationality received similar types of therapy, with glecaprevir/pibrentasvir being the most common... Differences in patient characteristics did not affect the effectiveness of the antiviral therapy, which exceeded 97% in both populations, but among Ukrainian patients, there was a higher percentage of people lost to follow-up."

Clinical • Gastroenterology • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes (EASL 2025) - "SVR rates were higher with newer pangenotypic regimens such as Epclusa (96.4%) and Maviret (96.2%) compared to older medications but markedly lower in DAA-experienced patients (85.0%) and those with moderate-to-low adherence (56.8%). This comprehensive decade-long analysis underscores critical insights into the management and outcomes of HCV in a large, population-based cohort, revealing that while high SVR rates are achievable, adherence remains a pivotal determinant of success. Our findings highlight specific subpopulations at risk for poor adherence and incomplete follow- up, emphasizing the need for targeted interventions to address these barriers in the pursuit of HCV eradication."

Adherence • Clinical • Addiction (Opioid and Alcohol) • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Obesity • Oncology • Psychiatry • Solid Tumor

Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving Direct-Acting Antivirals (DAAs) concomitantly with antipsychotic drugs in the US (EASL 2025) - "We explored the use of antipsychotic drugs in a US claims database concomitantly with the use of any of the two pangenotypic DAAs, sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB), evaluating the risk of associated DDIs, quality of the prescriptions based on the DDI risk, and the related healthcare resource use and costs. Despite the extended recognition of the use of the Liverpool HEP DDI tracker by all HCV treatment guidelines, this analysis of the DAAs based on the DDI risk demonstrates importance of safety monitoring of patients and the need for individualized medicine to ensure an appropriate DAA is used in patients with polypharmacy. Additionally, compared to GLE/PIB, SOF/VEL presents lower DDI risk and lower outpatient costs in the HCV patients receiving DAA treatment concomitantly with antipsychotic drugs."

Clinical • CNS Disorders • Hepatitis C

Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications (EASL 2025) - "While the effect of G/P on the exposures of these concomitant medications is expected to be small, herein we analyze the safety and tolerability of a subset of concomitant medications including antipsychotics (aripiprazole, quetiapine, risperidone, paliperidone, lurasidone, clozapine), cardiovascular agents (statins, beta-blockers, calcium-channel blockers, hypertensives) and opioids (fentanyl, oxycodone and hydrocodone). This integrated pooled analysis demonstrated that G/P when concomitantly administered with medications such as those belonging to the antipsychotic (aripiprazole, quetiapine, risperidone, paliperidone, lurasidone, clozapine), cardiovascular (statins, beta-blockers, calcium-channel blockers, hypertensives) and opioid class, was safe, well tolerated, and demonstrated high efficacy and adherence."

Clinical • Breast Cancer • Cardiovascular • CNS Disorders • Fibrosis • Hepatitis C • Hepatology • Immunology • Oncology • Solid Tumor

8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension (EASL 2025) - "Our real-world data support the use of an 8-week regimen of GP amongst patients with GT3 infection and cirrhosis. In a cohort of patients where 1 in 4 patients had CSPH and 1 in 3 had CPS6 or higher, SVR rates remained excellent irrespective of these baseline factors."

Clinical • Cardiovascular • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Portal Hypertension

Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s) (EASL 2025) - P3 | "G/P is highly effective, safe, and tolerable when used for treating acute or recently acquired HCV regardless of a history of prior HCV infections. These data provide insight into the role of prior infections in the management of acute infections in populations critical for HCV elimination."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Real-world efficacy and safety of universal 8-week Glecaprevir/Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan (EASL 2025) - "Eight-week GLE/PIB therapy was effective and well-tolerated in treatment-naïve patients with early CKD or pre-ESRD. Additionally, there was a significant improvement in renal function at SVR12 for both early CKD and pre-ESRD patients."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Inflammation • Metabolic Disorders • Nephrology • Renal Disease

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan. (PubMed, J Pharm Health Care Sci) - "A considerable proportion of patients were prescribed medications with DDI risk during DAA treatment. A small but notable proportion of patients were on "Contraindication (Red)" medications. Consideration of the potential DDI risks associated with comedications by healthcare professionals is advised, referring not only to package inserts but also tools such as Liverpool HEP checker to guide safe prescribing when initiating DAA therapy for HCV patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Pre-Transplant Initiation of Direct-Acting Antiviral Therapy for Donor-Derived Hepatitis C in a Pediatric Patient (ISHLT 2025) - "She started the first dose of glecaprevir/pibrentasvir (GLE/PIB; 300 mg/120mg) approximately 8 hours prior to transplant operating room arrival...Knowing HCV transmission can occur, it is important to consider pre-transplant DAA pharmacokinetics/pharmacodynamics and potential effects of cardiac bypass, among other factors. Ascertaining donor viral load and delineating early post-transplant viral load kinetics in the recipient could be important in guiding optimal dosing and timing of DAA before transplant and in guiding DAA duration post-transplant."

Clinical • Pre-transplantation • Cardiomyopathy • Cardiovascular • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pediatrics • Transplantation